Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation

Descripción del proyecto

Imagenología multiparamétrica basada en IA de glioblastomas para una estrategia de tratamiento personalizado

Los glioblastomas son el tipo de tumor maligno más frecuente y agresivo del sistema nervioso central. La heterogeneidad tumoral es el principal factor responsable de la elevada tasa de mortalidad de esta enfermedad, así como de su resistencia a tratamientos eficaces. El proyecto GLIOHAB, financiado con fondos europeos, desarrollará un sistema basado en la inteligencia artificial (IA) capaz de supervisar el estado funcional del glioblastoma a escala de píxel. El desarrollo de este «software» aprovecha tecnologías codesarrolladas, validadas y patentadas con anterioridad por el investigador del proyecto. GLIOHAB representa un esfuerzo multidisciplinario de los mejores expertos en aras de proporcionar las condiciones óptimas para un enfoque holístico del tratamiento del glioblastoma.

Objetivo

Glioblastoma is not only the most frequent but also the most malignant tumour originating in the Central Nervous System. Due to the extremely complex and heterogeneous molecular biology of this tumour “the same treatment for all” approach does not work well in this disease, and standard of care is not always the best option. The intra-patient tumor heterogeneity is one of the responsible factors for the high aggressiveness of these lethal solid tumors and their resistance against effective therapies. In this context, additional efforts are needed for generate novel strategies able to define more tailored personalized treatments that facilitate higher safety and efficacy for relevant sub-populations.
GLIOHAB project will develop an artificial intelligence based medical device able to monitor the functional state of the glioblastoma at pixel level. This software will be built on technologies previously co-developed, validated, and patented by the researcher. GLIOHAB will join best experts in the field, in a multidisciplinary and eminently clinical environment, which will provide the optimum conditions for a holistic approach to the solution. This proposal includes both the transfer of knowledge to the host institution and the training of the candidate in new advanced techniques. GLIOHAB results will contribute to monitor the response of highly aggressive tumours to complex treatments, and generate stratification strategies to select treatment responder patients.

Régimen de financiación

MSCA-IF-EF-ST - Standard EF

Coordinador

OSLO UNIVERSITETSSYKEHUS HF
Aportación neta de la UEn
€ 214 158,72
Dirección
KIRKEVEIEN 166 TARNBYGGET
0450 Oslo
Noruega

Ver en el mapa

Región
Norge Oslo og Viken Oslo
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 214 158,72